Delcath Systems (NASDAQ:DCTH – Get Free Report) and TerrAscend (OTCMKTS:TSNDF – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends.
Analyst Recommendations
This is a summary of current recommendations and price targets for Delcath Systems and TerrAscend, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Delcath Systems | 1 | 0 | 5 | 1 | 2.86 |
| TerrAscend | 0 | 1 | 0 | 1 | 3.00 |
Delcath Systems currently has a consensus price target of $23.17, suggesting a potential upside of 43.62%. Given Delcath Systems’ higher possible upside, equities analysts clearly believe Delcath Systems is more favorable than TerrAscend.
Volatility and Risk
Institutional and Insider Ownership
61.1% of Delcath Systems shares are owned by institutional investors. Comparatively, 5.8% of TerrAscend shares are owned by institutional investors. 19.4% of Delcath Systems shares are owned by insiders. Comparatively, 31.9% of TerrAscend shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Profitability
This table compares Delcath Systems and TerrAscend’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Delcath Systems | 0.56% | 0.46% | 0.42% |
| TerrAscend | -31.01% | -32.93% | -5.49% |
Valuation & Earnings
This table compares Delcath Systems and TerrAscend”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Delcath Systems | $95.42 million | 5.87 | $2.70 million | $0.01 | 1,613.00 |
| TerrAscend | $260.56 million | 0.80 | -$81.33 million | ($0.11) | -6.15 |
Delcath Systems has higher earnings, but lower revenue than TerrAscend. TerrAscend is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.
Summary
Delcath Systems beats TerrAscend on 10 of the 14 factors compared between the two stocks.
About Delcath Systems
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
About TerrAscend
TerrAscend Corp. cultivates, processes, and sells medical and adult use cannabis in Canada and the United States. The company produces and distributes hemp-derived wellness products to retail locations; and manufactures vaporizables, concentrates, topicals, tinctures and edibles. It also operates retail dispensaries under the Apothecarium and State Flower brand names. The company was incorporated in 2017 and is headquartered in Mississauga, Canada.
Receive News & Ratings for Delcath Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems and related companies with MarketBeat.com's FREE daily email newsletter.
